Opko Health, Inc. (OPK) Stock Price & How to Invest

OPKO Health, Inc. is a diversified healthcare company that operates across three areas. Its diagnostics business is anchored by BioReference Laboratories, a clinical lab whose revenue has been shrinking after the company sold certain assets (including oncology testing assets to Labcorp) and narrowed its geographic footprint to cut losses; its 4Kscore prostate-cancer test is a growth focus. Its pharmaceutical segment sells products such as Rayaldee (for secondary hyperparathyroidism) and earns a profit share on NGENLA, a long-acting growth-hormone product commercialized globally by Pfizer. Its third and most speculative piece is ModeX Therapeutics, a clinical-stage biotech developing multispecific antibodies and vaccines, including MDX2001, a tetraspecific T-cell engager for solid tumors that has advanced through early-stage dosing.

The investment picture in 2026 is a classic small-cap turnaround-plus-optionality story. Consolidated revenue has been declining, largely because of the BioReference asset sales and lower test volumes, and the company has continued to post net losses while working to reduce its operating loss through cost cuts and a more focused lab footprint. Management guided to a total-revenue range for 2026 alongside substantial continued R&D investment, signaling that it is spending to advance the ModeX pipeline. The bigger long-term value driver is ModeX's partnerships: collaborations with Merck (including a vaccine program) and Regeneron carry the potential for large milestone payments (Regeneron's deal was framed as potentially exceeding $200 million per program and over $1 billion in total if multiple products succeed). Because those milestones are contingent on clinical and commercial success, OPKO is best understood as a speculative, catalyst-driven stock rather than a steady earner.

The dominant risk is that OPKO has been unprofitable at the consolidated level, with declining revenue as BioReference shrinks, so the base business is not yet self-sustaining. The pipeline upside is highly speculative: ModeX's programs are early-stage, and clinical trials frequently fail, meaning the large partnership milestones may never be earned. Because it is a small-cap with ongoing losses, OPKO may need to raise capital, which could dilute existing shareholders, and the stock is volatile and sensitive to trial news and sentiment. The company's multi-segment structure (diagnostics, pharma, biotech) makes it harder to value and can obscure how each piece is really performing. Diagnostics faces reimbursement pressure and competition from much larger labs, while pharma revenue depends on a partner (Pfizer) for a key royalty. Litigation and regulatory history around the company and its founder have been a recurring overhang.

A simple financial snapshot. These are approximations and refresh quarterly; for current figures see Opko Health, Inc.'s investor relations page or your broker.

• Revenue trend: Declining, largely due to BioReference asset sales and lower test volumes; management guided 2026 total revenue to a range (roughly the low-to-mid-$500 millions). Figures are approximate, verify live.
• Profitability: Unprofitable at the consolidated level, posting net losses, though the operating loss has been narrowing on cost cuts and a more focused lab footprint.
• Balance sheet: Holds a meaningful cash position alongside debt (roughly balanced net cash/net debt in recent reporting). Confirm current cash and debt on the latest filing.
• Market cap tier: Small-cap. Approximate market value has been under roughly $1 billion. Verify the live number.
• Valuation note: Hard to value on earnings because the company loses money; the market prices it largely on pipeline optionality (ModeX) plus the diagnostics/pharma base. Multiples like P/E are not meaningful while losses persist.
• Analyst coverage: Followed by a modest number of analysts, with views split between pipeline optimists and turnaround skeptics. Check current ratings and targets live.

All figures here are approximate and tied to the asOf date; verify live numbers on a current quote page or the latest SEC filing before acting. Because OPKO is unprofitable, standard earnings multiples are not meaningful, and much of the stock's value rests on speculative, milestone-contingent pipeline outcomes at ModeX. Treat any partnership-value figures (such as the over-$1-billion Regeneron framing) as potential future milestones that require clinical and commercial success, not current revenue.

There are three common ways to get OPK exposure. Buy shares (or fractional shares) directly at any major broker. Hold an ETF that includes it, which spreads the position across many companies. Or build it into a focused thematic basket, so OPK sits alongside other stocks that express the same thesis.

Walnut takes the basket route. Describe a thesis where OPK fits (for example “AI infrastructure” or “dividend-growth large-caps”) and the AI proposes 5 to 6 constituents with target weights. You review the plan and fund it through your own broker when you're ready.

OPKO Health is a small-cap, multi-part healthcare company: a restructuring diagnostics arm, a modest pharma franchise, and a clinical-stage antibody platform (ModeX) with Merck and Regeneron partnerships. The upside is pipeline-driven and speculative; the base business has been loss-making, so it suits higher-risk, patient investors.